Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Avalo Therapeutics (AVTX) Net Margin (2016 - 2025)

Avalo Therapeutics (AVTX) has disclosed Net Margin for 8 consecutive years, with 18405.73% as the latest value for Q4 2024.

  • For the quarter ending Q4 2024, Net Margin fell 1697526.0% year-over-year to 18405.73%, compared with a TTM value of 52019.79% through Sep 2025, down 5104930.0%, and an annual FY2024 reading of 7965.76%, down 632626.0% over the prior year.
  • Net Margin was 18405.73% for Q4 2024 at Avalo Therapeutics, down from 9251.81% in the prior quarter.
  • Across five years, Net Margin topped out at 9251.81% in Q3 2024 and bottomed at 18405.73% in Q4 2024.
  • Average Net Margin over 4 years is 1156.94%, with a median of 26.27% recorded in 2021.
  • Peak annual rise in Net Margin hit 1146706bps in 2024, while the deepest fall reached -1697526bps in 2024.
  • Year by year, Net Margin stood at 33.34% in 2020, then tumbled by -190bps to 30.14% in 2021, then tumbled by -4647bps to 1430.47% in 2023, then crashed by -1187bps to 18405.73% in 2024.
  • Business Quant data shows Net Margin for AVTX at 18405.73% in Q4 2024, 9251.81% in Q3 2024, and 1430.47% in Q4 2023.